Antagonists Against Interaction of Pf4 and Rantes

A polypeptide, its pharmacologically acceptable salts, derivatives and/or conjugates, having an amino acid sequence SEQ ID NO. 1 according to formula (1) as given below:

• (SEQ ID NO. 1)
• C-X1-X2-YFYTS-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-C (1)
• wherein:
• X1 is selected from the group consisting of lysine, glutamine, arginine, histidine and asparagine, or
• is an amino acid deletion;
• X2 is selected from the group consisting of glutamic acid, aspartic acid and glutamine, or
• is an amino acid deletion;
• X3 is selected from the group consisting of glycine, serine and alanine;
• X4 is selected from the group consisting of lysine, leucine and arginine;
• X5 is selected from the group consisting of serine, cysteine, glycine and threonine;
• X6 is selected from the group consisting of serine, glycine and threonine;
• X7 is selected from the group consisting of asparagine and glutamine;
• X8 is selected from the group consisting of proline, tyrosine and glycine;
• X9 is selected from the group consisting of glycine, alanine and serine;
• X10 is selected from the group consisting of isoleucine, valine and asparagine;
• X11 is selected from the group consisting of valine, isoleucine and asparagine;
• X12 is selected from the group consisting of phenylalanine, tyrosine, isoleucine, valine, leucine and methionine;
• X13 is selected from the group consisting of isoleucine, valine, leucine, methionine and phenylalanine;
• X14 is selected from the group consisting of threonine, glycine, alanine, serine and tyrosine;
• X15 is selected from the group consisting of arginine, lysine, glutamine, histidine and asparagine, or
• is an amino acid deletion.